XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Equity-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Schedule of Equity-Based Compensation Expense

Equity-based compensation expense is classified in the condensed consolidated statements of operations and comprehensive loss as follows:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In thousands)

 

Research and development

 

$

9,017

 

 

$

2,775

 

 

$

18,643

 

 

$

7,325

 

General and administrative

 

 

6,393

 

 

 

2,625

 

 

 

13,805

 

 

 

6,996

 

Total

 

$

15,410

 

 

$

5,400

 

 

$

32,448

 

 

$

14,321

 

Summary of Restricted Stock Activity

The following table summarizes the Company’s restricted stock activity for the nine months ended September 30, 2021:

 

 

Number of
Shares

 

 

Weighted
Average Grant
Date Fair Value
per Share

 

Unvested restricted stock units as of December 31, 2020

 

 

193,936

 

 

$

23.98

 

Granted

 

 

354,072

 

 

 

63.13

 

Vested

 

 

(50,946

)

 

 

17.80

 

Cancelled

 

 

(53,777

)

 

 

38.02

 

Unvested restricted stock units as of September 30, 2021

 

 

443,285

 

 

$

54.26

 

Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted Weighted average assumptions used to apply this pricing model were as follows:

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2021

 

2020

 

2021

 

2020

Risk-free interest rate

 

1.0%

 

0.4%

 

0.9%

 

0.9%

Expected life of options

 

6.0 years

 

6.0 years

 

6.0 years

 

5.5-6.0 years

Expected volatility of underlying stock

 

75.2%

 

70.8%

 

72.7%

 

67.6%

Expected dividend yield

 

0.0%

 

0.0%

 

0.0%

 

0.0%

Summary of Stock Option Activity The following is a summary of stock option activity for the nine months ended September 30, 2021:

 

 

Number of
Options

 

 

Weighted
Average
Exercise
Price per
Share

 

 

Weighted
Average
Remaining
Contractual
Term

 

 

Aggregate
Intrinsic
Value

 

 

 

 

 

 

 

 

 

(In years)

 

 

(In thousands)

 

Outstanding at December 31, 2020

 

 

6,977,440

 

 

$

15.43

 

 

 

 

 

 

 

Granted

 

 

2,435,102

 

 

 

79.17

 

 

 

 

 

 

 

Exercised

 

 

(2,636,437

)

 

 

15.12

 

 

 

 

 

 

 

Forfeited

 

 

(559,241

)

 

 

29.80

 

 

 

 

 

 

 

Outstanding at September 30, 2021

 

 

6,216,864

 

 

$

39.23

 

 

 

8.01

 

 

$

601,927

 

Exercisable at September 30, 2021

 

 

1,977,984